#1 Clinical Trials Search in Europe

MAGNESIUM CARBONATE HEAVY

Clinical trials investigating “MAGNESIUM CARBONATE HEAVY” are studying treatment for people with dyspepsia, also called indigestion. The trials aim to compare symptom improvement and help show whether a shorter treatment plan works as well as a longer one. They focus on patients with unexplained dyspepsia.

Table of contents

Trial overview

This clinical trial is studying MAGNESIUM CARBONATE HEAVY in people with dyspepsia, which means indigestion.[1] The study is titled as a randomized, non-inferiority trial and is authorised.[1]

The trial compares 7-day treatment with 4-week treatment in patients with unexplained dyspepsia.[1] The main question is whether the shorter treatment plan works well enough compared with the longer plan.[1]

Study design and phase

This is an interventional study, which means the researchers give a treatment and then measure the results.[1] It is in Phase 3, a later stage of research that usually checks how well a treatment works in a larger group of people.[1]

The trial plans to enroll 128 participants.[1] It is also described as randomized, which means people are assigned to a treatment group by chance.[1]

Who can join the study

The target population is patients with unexplained dyspepsia.[1] The source data does not give more detailed inclusion or exclusion rules, so the main known requirement is the condition being studied.[1]

Because the trial focuses on unexplained dyspepsia, it is meant for people whose indigestion symptoms are being evaluated in this study setting.[1]

What is being measured

The main outcome is the change in the modified Glasgow Dyspepsia Severity Score (GDSS).[1] This score is used to measure how severe dyspepsia symptoms are, so the study can track whether symptoms improve over time.[1]

The trial compares the change from Week 1, which covers Days 1 to 7, to Weeks 2 to 4, which cover Days 8 to 28.[1] The treatment effect is the difference between the two study groups, and the non-inferiority margin is 2 points.[1]

Why this trial matters

This study is looking at whether a shorter treatment course can be close enough to a longer course for symptom control in dyspepsia.[1] If the shorter plan performs well, it may help answer an important practical question for patients and researchers about treatment length.[1]

Because the trial is focused on symptoms rather than a disease cure, its main value is in understanding how treatment duration affects patient-reported discomfort.[1]

Trial ID Phase Condition studied Status Enrollment
2025-524044-35-00 Phase 3 Dyspepsia Authorised 128

FAQ

  • What are the clinical trials of MAGNESIUM CARBONATE HEAVY studying? They are studying symptom relief in people with dyspepsia. The main goal is to compare how symptoms change over time between two treatment lengths.
  • Who can take part in these trials? The trial is for patients with unexplained dyspepsia. The source data does not list more detailed entry rules.
  • What phase is the trial? The trial is in Phase 3. This means it is a later-stage study that looks closely at how well the treatment works.
  • What treatment lengths are being compared? The study compares 7 days versus 4 weeks of treatment. It is designed as a non-inferiority trial, which means it checks whether the shorter plan is not meaningfully worse than the longer one.
  • What outcome is being measured? The main outcome is the change in the modified Glasgow Dyspepsia Severity Score, or GDSS. This score measures how bad the symptoms are, and the trial compares the difference between the two treatment groups.

Ongoing Clinical Trials on MAGNESIUM CARBONATE HEAVY

  • Comparing 7-Day and 4-Week Esomeprazole Treatment in Patients with Unexplained Dyspepsia

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Iceland

Glossary

  • Dyspepsia: A medical term for indigestion. It can include discomfort or pain in the upper stomach area, bloating, or feeling full too soon.
  • Unexplained dyspepsia: Dyspepsia where the cause is not clearly known from the trial data.
  • Phase 3: A later stage of clinical research that checks how well a treatment works in a larger group of people.
  • Interventional study: A study where researchers give a treatment and then measure the results.
  • Randomized: Participants are assigned by chance to different treatment groups.
  • Non-inferiority trial: A study designed to show that one treatment is not much worse than another treatment by more than a set limit.
  • Glasgow Dyspepsia Severity Score (GDSS): A symptom score used to measure how severe dyspepsia is. Higher or lower scores show how symptoms change over time.
  • Primary outcome: The main result the study is designed to measure.
  • Enrollment: The number of people planned to join the study.

References

  1. https://clinicaltrials.gov/study/2025-524044-35-00